Cohance Lifesciences Changes Website Address Post Name Change
Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, has officially changed its website address from www.suvenpharm.com to www.cohance.com. This update follows the company's recent name change and has been communicated to the stock exchanges.
A change in website address is a standard procedural update and typically has minimal direct impact on the company's business operations, financial performance, or stock price.
The announcement is a routine administrative update regarding a website change following a company name change. It does not contain any financial or operational information that would suggest a positive or negative sentiment.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has announced a change in its official website address. The new website will be accessible at www.cohance.com, replacing the previous address, www.suvenpharm.com. This change is a consequence of the company's recent name change.
The company has formally informed both the BSE Limited and the National Stock Exchange of India Limited about this update, providing the necessary details for their records. The communication was sent on December 13, 2025.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under other company updates. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.